The novel treatment of this peptide represents a major development in the handling of diabetes mellitus type 2. Distinct from existing drugs, tirzepatide affects two pathways – glucagon-like peptide-1 (GLP-1) and GIP – providing enhanced blood sugar management and anticipated weight reduction. Re